



# Seroprevalence of Asymptomatic *Leishmania* spp. Carriage Among Blood Donors in Leishmaniasis Endemic Area in Turkey

## Türkiye’de Layşmanyazisin Endemik Olduğu Bölgede Kan Bağışçılarında Asemptomatik *Leishmania* spp. Taşıyıcılığının Seroprevalansı

Gül BAYRAM<sup>1</sup>([iD](#)), Ender DİNÇER<sup>2</sup>([iD](#)), Sema ERDEN ERTÜRK<sup>3</sup>([iD](#)), Eyüp Naci TİFTİK<sup>4</sup>([iD](#))

<sup>1</sup> Medical Laboratory Techniques, Department of Medical Services and Techniques, University of Mersin Health Services Vocational School, Mersin, Turkey

<sup>2</sup> University of Mersin Advanced Technology Education Research and Application Center, Mersin, Turkey

<sup>3</sup> University of Mersin Health Services Vocational School, Mersin, Turkey

<sup>4</sup> Department of Internal Medicine, Faculty of Medicine, University of Mersin, Mersin, Turkey

**Cite this article as:** Bayram G, Dinçer E, Erden Ertürk S, Tiftik EN. Seroprevalence of asymptomatic *Leishmania* spp. carriage among blood donors in leishmaniasis endemic area in Turkey. FLORA 2020;25(1):33-9.

### ABSTRACT

**Introduction:** Transfusion-related infections are usually caused by a microbial pathogen transmitted to the recipient by the donated blood. *Plasmodium* spp., *Trypanosoma cruzi*, *Babesia microti*, *Toxoplasma gondii* and *Leishmania* spp. are listed as the most widely reported transfusion-transmitted parasites. Leishmaniasis is well known as an endemic in Mediterranean countries including Turkey. Accordingly, detection of asymptomatic *Leishmania infantum* carriage in blood donors is an important issue in Turkey. In endemic territories, research on blood donors is under-represented in Turkey. Likewise, Mersin province is also endemic for Leishmaniasis. Up to date, no studies have been conducted to detect Leishmaniasis in healthy blood donors in our region. Therefore, the main objective of the current study was to reveal the seroprevalence of asymptomatic *Leishmania* carriage among the blood donors in Mersin province.

**Materials and Methods:** A total of 509 blood samples were collected from blood donors during a 12-month period between June 2016 and June 2017 at Mersin University Health Research and Application Center. Collected questionnaires were evaluated to determine the risk of exposure to *Leishmania* spp. Serological and molecular methods were assessed on the collected blood specimens.

**Results:** Based on the questionnaires, a total number of 509 donors participated the study, living in the city center (n= 367), district (n= 121), town (n= 7) and village (n= 14) respectively. A veterinarian and a sailor as well as 17 farmers were listed in the risky occupational groups. The number of dog and cat owner donors were reported as 41 and 20, respectively. All samples were found to be negative for *Leishmania* spp. by ELISA and real-time polymerase chain reaction methods.

**Conclusion:** This research is the first to assess Leishmaniasis risk in Mersin province. It is highly recommended not to utilize *Leishmania* spp. screening into the routine test packages in blood banks in our region.

**Key Words:** Transfusion-related infection; Blood donor; Endemic; *Leishmania* spp.

## ÖZ

### Türkiye’de Layşmanyazisin Endemik Olduğu Bölgede Kan Bağışçılarında Asemptomatik *Leishmania* spp. Taşıyıcılığının Seroprevalansı

GÜL BAYRAM<sup>1</sup>, Ender DİNÇER<sup>2</sup>, Sema ERDEN ERTÜRK<sup>3</sup>, Eyüp Naci TİFTİK<sup>4</sup>

<sup>1</sup> Mersin Üniversitesi Sağlık Hizmetleri Meslek Yüksekokulu, Tıbbi Hizmetler ve Teknikler Bölümü, Tıbbi Laboratuvar Teknikleri, Mersin, Türkiye

<sup>2</sup> Mersin Üniversitesi İleri Teknoloji Eğitim Araştırma ve Uygulama Merkezi, Mersin, Türkiye

<sup>3</sup> Mersin Üniversitesi Sağlık Hizmetleri Meslek Yüksekokulu, Mersin, Türkiye

<sup>4</sup> Mersin Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Mersin, Türkiye

**Giriş:** Transfüzyonla ilişkili infeksiyonlara genellikle alıcıya bağışlanan kanla bulaşan mikrobiyal bir patojen neden olmaktadır. En yaygın olarak rapor edilen transfüzyonla bulaşan parazitler *Plasmodium* spp., *Trypanosoma cruzi*, *Babesia microti*, *Toxoplasma gondii* ve *Leishmania* spp.’dir. Layşmanyazis, Türkiye’nin de içinde bulunduğu Akdeniz ülkelerinde endemiktir. Kan bağışçılarında asemptomatik *Leishmania infantum* taşıyıcılığının saptanması önemli bir noktadır. Endemik bölgelerde kan bağışçılarında gerçekleştirilen çalışma sayısı sınırlıdır. Mersin ili layşmanya için endemiktir. Daha önce bölgemizdeki sağlıklı kan bağışçılarında layşmanyazisi tespit etmek için herhangi bir çalışma yapılmamıştır. Bu çalışmanın amacı, Mersin ilindeki kan bağışçılarında asemptomatik layşmanya taşıyıcılığının seroprevalansını belirlemektir.

**Materyal ve Metod:** Haziran 2016-Haziran 2017 tarihleri arasında, 12 aylık sürede Mersin Üniversitesi Sağlık Araştırma ve Uygulama Merkezinde kan bağışçılarında toplam 509 kan örneği toplandı. *Leishmania* spp. ‘ye maruz kalma riskini belirlemek için anket çalışması yapıldı. Toplanan kan örnekleri serolojik (ELISA) ve moleküler yöntemlerle [gerçek-zamanlı polimeraz zincir reaksiyonu (RT-PCR)] çalışıldı.

**Bulgular:** İl merkezinde, semtte, kasabada ve köyde yaşayan kan bağışçısı sayısı anket sonuçlarına göre 367, 121, 7 ve 14’tür. Kan bağışçıları arasındaki riskli meslek grupları değerlendirildiğinde; sadece bir bağışçı veteriner, biri denizci ve 17’si çiftçidir. Kırk bir bağışçı köpek, 20 bağışçı kedi sahibidir. Toplanan kan örneklerinin tamamı ELISA ve RT-PCR ile *Leishmania* spp. için negatif olarak saptanmıştır.

**Sonuç:** Bu araştırma Mersin ilinde kan donörlerinde layşmanya riskini değerlendiren ilk araştırmadır. Bölgemizde *Leishmania* spp. belirlenmesine yönelik testlerin transfüzyon tarama testleri içerisine dahil edilmesi gerekliliği yoktur.

**Anahtar Kelimeler:** Transfüzyonla bulaşan infeksiyon; Kan bağışçısı; Endemik; *Leishmania* spp.

## INTRODUCTION

Leishmaniasis is a parasitic infection transmitted by an insect vector infected by protozoa of the genus *Leishmania* (*Trypanosomatida: Trypanosomatidae*). This parasite is a threatening factor in approximately 100 countries including tropical, subtropical and Mediterranean areas<sup>[1]</sup>. In endemic regions, 350 million of the population is estimated to be in danger in terms of leishmaniasis disease. It is reported that 12 million people are infected with *Leishmania* spp. worldwide. It has been found that 15 species of *Leishmania* spp. are related with infections in human and the main reservoir of 13 among all has been found in canidae and rodents<sup>[2]</sup>. On the other hand, Turkey is endemic for both cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). Up to

date, Leishmaniasis cases in Turkey have usually occurred in Eastern Anatolia, Central Anatolia, Aegean, Mediterranean regions<sup>[3]</sup>. VL is generally known to affect the internal organs especially the spleen, liver and bone marrow resulting in high fever, weight loss, anemia, leukopenia, thrombocytopenia, splenomegaly and hepatomegaly<sup>[4]</sup>. VL is endemic in over 88 countries in tropical and subtropical regions. Annually, 90% of the 500.000 VL cases are reported in Nepal, Bangladesh, India, Sudan, Brazil, especially in the male sex<sup>[5]</sup>.

*Leishmania* is not only transmitted by the bite of infected female sandflies, but also by congenital, blood transfusion, organ transplantation, laboratory accidents and needle-sharing in drug users<sup>[6,7]</sup>. The prevalence of asymptomatic carriers of infection is a significant factor in en-

demic regions. Although Turkey is endemic for leishmaniasis, the number of studies performed in asymptomatic population appears highly poor<sup>[8,9]</sup>. Blood donors can be considered as a crucial group in these asymptomatic population. Besides, in our region, no studies have been carried out in blood donors so far. Based on the above rationale, the main objective of the current study was to investigate the prevalence of *Leishmania* spp. in blood donors by employing serological and molecular methods in Mersin province.

## MATERIALS and METHODS

### Collection of Blood Samples

In total, 509 healthy blood donors without a history of VL were included into the study. Blood samples were collected from volunteers in a 12-month period between June 2016 and June 2017 at Mersin University Health Research and Application Center. Blood samples (5 mL) were collected from the donors into EDTA-coated tubes. According to the permission of Mersin University clinical research ethics committee (ethics committee number: 2016/141), all donors were informed regarding the routine procedures for sampling. Questionnaires were prepared to evaluate the risk of exposure to *Leishmania* spp. infection. Each questionnaire was composed of 12 questions including the donors' age, sex, living area, occupation, working hours, working place, dog or cat ownership and awareness about Leishmaniasis.

### Statistical Analysis

Power analysis was performed. The statistical analysis was determined as the ratio comparison. In the study,  $\alpha = 0.05$ , the power of the test = 0.80 and the minimum sample size were calculated as 500.

### ELISA Method

Sera of the collected blood samples were separated by centrifugation at 5000 rpm for 5 min and stored at  $-20^{\circ}\text{C}$  until use. Thereafter, sera samples were utilized with NovaLisa *L. infantum* IgG, ELISA Kit (Handels GmbH & Co KG, Austria) according to manufacturers' procedures. Specificity and sensitivity of the test were defined as 85-91%, respectively. The cut off value was determined as 0.150-0.130.

### DNA Isolation

Genomic DNA of whole blood specimens were extracted by using High Template Preparation Kit (Roche, Germany). DNA concentration was measured spectrophotometrically by CapitalBio NanoQ drop (China). All isolated DNA samples were stored at  $-20^{\circ}\text{C}$  until use.

### Real-time Polymerase Chain Reaction (RT-PCR)

RT-PCR was performed for the detection of *Leishmania* spp. Primary and probe designs were used as previously<sup>[10]</sup>. 15 pmol F- 5'- CTTTTCGTGGTCC TCCGGGTAGG-3', R- 5'- CCACC-CGGCCCTATTTTAC ACCAA- 3' and 50 pmol probe FAM-5'- TTTTCGCAGAACGCCCTACC-CGC-3'- TAMRA sequences were used<sup>[10]</sup>. *L. major* (KM555292), *L. tropica* (MH511156), *L. donovani* (KU899560) and *L. infantum* (KC536649) are recognized by these primer sequences. A single-stage real-time PCR was performed in the study. PCR mix containing 10  $\mu\text{L}$  TaqMan Universal Master Mix II (Applied Biosystem, USA), 1  $\mu\text{L}$  primer/probe (10 pmol RV1-F, RV1-R and 0.5 pmol RV- P), 4  $\mu\text{L}$  RNase/DNase free distilled water were used for the master mix. 5  $\mu\text{L}$  isolated DNA sample added to the mix. VIIA7 device (Applied Biosystem, USA) was used for the real-time PCR assay. RT-PCR reaction was performed along with the positive and negative controls. Molecular grade water (Thermoscientific, Lithuania) was used as a negative control. *L. infantum* (MHOM/TR/19/BSK-INF) and *L. tropica* (MHOM/TR/19/BSK-TRO) strains were used as positive controls. Beta-globin gene was used as an endogenous control to normalize initial DNA concentrations to confirm sample integrity. Beta-globin gene was used as an internal positive control in RT-PCR analysis. The beta-globin gene primers/probe were as described previously<sup>[11]</sup>. Primers and probes consisted of beta-globin-F-5'-GTCACCTGACTCCTGAGGAGA-3'; beta-globin-R-5'-CCTTGATACCAACCTGCCAG-3'; and probe'; beta-globin-5'-(FAM)-AAGGTGAACGTGGATGAAGTTGGTGG-(TAMRA)-3'. Identical thermal profiles were performed for both *Leishmania* spp. and beta-globin. Initial denaturation  $94^{\circ}\text{C}$  for 10 minutes followed by 40 cycles of denaturation at  $94^{\circ}\text{C}$  for 15 seconds and exten-

sion at 60°C for 1 minute. PCR mix containing 10 µL TaqMan Universal Master Mix II (Applied Biosystem, USA), 1 µL primer/prob (10 pmol RV1-F, RV1-R and 0.5 pmol RV-P), 4 µL RNAse/DNAse free distilled water were used for the master mix. 5 µL isolated DNA sample added to the mix. VIIA7 device (Applied Biosystem, USA) was used for the real-time PCR assay.

## RESULTS

Study population was composed of 509 donors (24 females and 485 males) with an average age of 34. Collected from the questionnaires, living area of the donors was distributed as follows: in the city center (n= 367), district (n= 121), town (n= 7) and village (n= 14). Among all, a veterinarian and a sailor as well as 17 farmer donors were classified in the risky occupational group (Table 1). Among pet (41 dogs or 20 cats) owner donors, only 3 (dog) or 10 (cat) of them were feeding their pets at home. Addi-

tionally, 10 of the donors were listed as having fed cat in the past. Results of the questionnaire were summarized in Table 1. Determined via ELISA application all the donors were serologically negative, while there was no detectable *Leishmania* spp. at the blood donors tested by RT-PCR.

## DISCUSSION

Climate change and migration have increased the incidence of rare and neglected diseases in recent years. In particular, leishmaniasis has started to be reported in non-endemic areas due to the migration from endemic regions to non-endemic regions through international travel<sup>[12-15]</sup>. The parasitic concentration in asymptomatic VL carriers has been reported to be quite low with the absence of clinical and hematological alterations that masks the disease<sup>[16]</sup>. However, the presence of antibodies against parasites do not always indicate active infection. Likely, antibodies can be a sign for risk of parasitic encounter<sup>[17]</sup>.

**Table 1. Questionnaire results**

Questionnaire questions	%
Sex	5 females 95 males
Location	72 city center 24 district 1.3 town 2.7 village
Risky occupation	3.3 farmer 0.1 sailor 0.1 veterinarian 96.5 others
Work place	46 office 4.5 farm 4.2 hospital 55 construction, factory and shopping center
Information about leishmania	4.3 yes 95.7 no
Dog owners	0.59 in house 7.5 outside the house
Not have a dog	89.9
Had a dog	1.9
Cat owners	2.4
Not have a cat	95.7
Had a cat	1.9

It has been declared that the parasite can survive until 15 days in red blood cells depending on the storage conditions in blood banks<sup>[18]</sup>. In recent years, various techniques have been used for pathogen inactivation during blood components preparation process. In our study, neither inactivation nor filtration processes were utilized when processing the samples. This situation can easily create a risk for blood transfusion process especially in endemic regions. Therefore, the detection of leishmaniasis during transfusion process is a vital matter. There are several gold standard methods used in the diagnosis of active *Leishmania* infection but, none of these methods are often practical nor cost effective for epidemiological studies<sup>[17]</sup>. In the recent years, fortunately, nucleic acid-based amplification methods have paved the way to detect *Leishmania* spp. without invasive methods<sup>[19]</sup>. Additionally, serological methods are also being used to detect Leishmaniasis in asymptomatic carriers as well as molecular methods<sup>[20-22]</sup>. There are various studies conducted with serological methods to investigate *Leishmania* spp. in blood donors. In one of the studies, *L. infantum* has been reported to be positive in 8% of the Spanish blood donors by immunofluorescence assay (IFA)<sup>[20]</sup>. *L. braziliensis* has been found to be 11.4% in Brazilian blood donors with an other technique, enzyme immunoassay (EIA)<sup>[21]</sup>. *Leishmania* IgG seropositivity was determined as 5% in Nepal at blood donors<sup>[22,23]</sup>. In Turkey, on the other hand, VL is mostly seen in the Aegean and Mediterranean regions. Besides, there are certain reported cases from other regions as well<sup>[24-28]</sup>. Until now, Ateş et al. is the only group that investigated leishmaniasis at blood donors in Turkey<sup>[8,9]</sup>. Revealed by two methods, Ateş et al. have detected anti-leishmanial antibodies 6.4% by IFAT and 0.5% by ELISA<sup>[8]</sup>. In another study from 2013, the same investigators determined 2.6% and 2% positive anti-leishmanial antibodies by ELISA and IFAT methods respectively in 343 sera samples of donors<sup>[9]</sup>. The sensitivity ratios of these methods were graded as follows: microculture method (MCM) 71%, smear 19%, IFAT 33%, ELISA (42%), traditional culture (NNN) 4%, PCR (14%) and immunochromatographic test (ICT) 4%. Worldwide, *Leish-*

*mania* spp. rate is declared as 4-8.7% in blood donors<sup>[29]</sup>. Interestingly, based on annual reports, infected blood donors are listed more often from Brasil, Nepal, Bangladesh and India rather than the rest<sup>[30]</sup>. Blood donations by immigrants from endemic areas is a vital issue in transfusion safety. Indeed, the Mersin province is endemic for leishmaniasis and hosts approximately 206.000 refugees (11.5% of the population) who escaped from the civil war in Syria<sup>[31]</sup>.

Due to the migration from *Leishmania* endemic of Turkey, it was declared that 1.578 (3.43%) CL cases were detected in Mersin between 1990-2010<sup>[32]</sup>. Although the Mediterranean region is endemic for Leishmaniasis, no studies have been conducted yet on *Leishmania* spp. issue in blood donors. In this study, 509 donors were evaluated for asymptomatic *Leishmania* spp. carriage by serologic and molecular methods. As a result of study, all of the donors were detected seronegative for *Leishmania* spp. However, DNA samples of the donors were determined negative by RT-PCR. Negative results are considered to be related to the environment and working conditions of the donor population. The number of donors engaged in farming was 3.3% and most of the donors worked in the office (46%) and lived in the city center (72%). Therefore, the risk for these donors to encounter with the vector decreases compared to those living in rural areas. Previous studies have reported that stray dogs and cats were risk factors for transmission of *leishmania* infection to humans<sup>[33,34]</sup>. *Leishmania* spp. infection in domestic cats and dogs can be rare or under-reported in endemic areas. Dog ownership is an important factor for *Leishmania* spp. carriage. As a result of the survey in this study, only 0.59% of the donors were caring dogs in the house and 7.5% of them were caring outside, 1.9% of donors had dog care in the past and 89% of the donors did not own any dogs. Other than dog ownership, domestic and stray cats are also reported as risk factors to possess *Leishmania* infection<sup>[35,36]</sup>. Mondolfi et al. have reported *L. mexicana* in both cats and dogs in their study<sup>[37]</sup>. Coura et al. have collected 100 feline serum samples and found positive *Leishmania* antibodies in 54 sera samples

by IFAT<sup>[38]</sup>. *Leishmania* infection was first reported in cats of Turkey by Can et al. Researchers detected seropositive rates 10.8% and 15.2% by ELISA and IFA methods<sup>[35]</sup>. Also, *L. tropica* was determined in six cats and *L. infantum* was detected in one cat in that study. In another study conducted in Turkey, Pasa et al. have reported 8.84% *Leishmania* spp. positivity by PCR in domestic cats. They have found *L. major* and *L. tropica* infections in domestic cats<sup>[36]</sup>. In our study, 2.4% donors were feeding cats at home and 1.9% donors had a cat in the past. 95.7% the donors had no cats. Low rates of dog ownership and cat ownership are considered as other factors for negative results in this study.

Finally, asymptomatic blood donors from endemic areas have been reported from various countries but there are still limited studies performed in blood donors for leishmaniasis detection. The results obtained from this study are the first ever reported for our region. Until now, there isn't any conducted research in the Mediterranean region. Thus, we suggest that it is essential to perform new investigations in nearby provinces, especially bearing wider populations. However, the risk for transmission of VL through blood transfusion is ignored in this research. It is not suggested to set up routine screening for *Leishmania* spp. infection in blood transfusion departments located in Mersin province.

#### ACKNOWLEDGEMENT

This study was supported by Mersin University Scientific Research and Project Unit as a project no. 2016-2-AP4-1923.

#### CONFLICT of INTEREST

Authors have no competing interests to disclose.

#### AUTHORSHIP CONTRIBUTIONS

Concept/Design: GB

Analysis/Interpretation: GB, ED, SEE

Data Acquisition: GB, ENT

Writting: GB, ED

Final Approval: GB

#### REFERENCES

1. Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. *Trends Parasitol* 2002;18:399-405.
2. Gramiccia M, Gradoni L. The current status of zoonotic leishmaniasis and approaches to disease control. *Int J Parasitol* 2005;35:1169-80.
3. Available from: [http://www.who.int/leishmaniasis/burden/Leishmaniasis\\_Turkey/en/2018.23.10](http://www.who.int/leishmaniasis/burden/Leishmaniasis_Turkey/en/2018.23.10).
4. Control of the leishmaniasis. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniasis. 22-26, March, 2010.
5. Lindoso JA, Lindoso AA. Neglected tropical diseases in Brazil. *Rev Inst Med Trop Sao Paulo* 2009;51(5):247-53.
6. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. *Clin Microbiol Rev* 2001;14:659-88.
7. Colomba C, Saporito L, Polara VF, Barone T, Corrao A, Biglino A, et al. Asymptomatic *Leishmania infantum* infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonendemic. *J Clin Microbiol* 2010;48:131-6.
8. Ates SC, Bagirova M, Allahverdiyev AM, Baydar SY, Koc RC, Elcicek S, et al. Detection of antileishmanial antibodies in blood sampled from blood bank donors in Istanbul. *Future Microbiol* 2012;7:773-9.
9. Ates SC, Bagirova M, Allahverdiyev AM, Kocazeybek B, Kocan E. Utility of the microculture method for *Leishmania* detection in non-invasive samples obtained from a blood bank. *Acta Trop* 2013;128:54-60.
10. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of *Leishmania infantum* DNA by a real-time PCR assay with high sensitivity. *J Clin Microbiol* 2004;42(11):5249-55.
11. Lo Ym, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. *Am J Hum Genet* 1998;62(4):768-75.
12. Ozkeklikci A, Karakus M, Ozbel Y, Toz S. The new situation of cutaneous leishmaniasis after Syrian civil war in Gaziantep city, Southeastern region of Turkey. *Acta Trop* 2017;166:35-8.
13. Artun O, Kavur H. Prediction of cutaneous leishmaniasis epidemiology in Mersin using ecological niche modeling. *Turkiye Parazitoloj Derg* 2018;42(3):191-5.
14. Söbirk SK, Inghammar M, Collin M, Davidsson L. Imported leishmaniasis in Sweden 1993-2016. *Epidemiol Infect* 2018;146:1267-74.
15. Fotakis EA, Giantsis IA, Avgerinou A, Kourtidis S, Agathaggelidou E, Kapoula C, et al. Identification of *Leishmania* species in naturally infected sand flies from refugee camps, Greece. *Emerg Infect Dis* 2019;25(2):361-4.
16. Tiburcio MG, Anversa L, Kanunfre KA, Ferreira AW, Rodrigues Junior V, Silva Lde A. Anti-*Leishmania infantum* IgG antibody avidity in visceral leishmaniasis. *Clin Vaccine Immunol* 2013;20(11):1697-702.

17. Riera C, Fisa R, Udina M, Gallego M, Portus M. Detection of *Leishmania infantum* cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. *Trans R Soc Trop Med Hyg* 2004;98:102-10.
18. Grogl M, Daugirda JL, Hoover DL, Magill AJ, Berman JD. Survivability and infectivity of viscerotropic *Leishmania tropica* from Operation Desert Storm participants in human blood products maintained under blood bank conditions. *Am J Trop Med Hyg* 1993;49:308-15.
19. Martin-Sanchez J, Pineda JA, Morillas-Marquez F, Garcia Garcia JA, Acedo C, Macias J. Detection of *Leishmania infantum* kinetoplast DNA in peripheral blood from asymptomatic individuals at risk for parenterally transmitted infections: relationship between polymerase chain reaction results and other *Leishmania* infection markers. *Am J Trop Med Hyg* 2004;70:545e8.
20. Monteiro DCS, Sousa AQ, Lima DM, Fontes RM, Praci-ano CC, Frutuoso MS. *Leishmania infantum* infection in blood donors, North eastern Brazil. *Emerg Infect Dis* 2016;4(22):739-40.
21. Braga LS, Navasconi TR, Leatte EP, Skraba CM, Silveira TGV, Ribas-Silva RC. Presence of anti-*Leishmania* (*Viannia*) *braziliensis* antibodies in blood donors in the West-Central region of the State of Parana, Brazil. *Rev Soc Bras Med Trop* 2015;448(5):622-5.
22. Fukutani KF, Figueiredo V, Celes FS, Cristal JR, Barral A, Bar-ral-Netto M. Serological survey of *Leishmania* infection in blood donors in Salvador, Northeastern Brazil. *BMC Infect Dis* 2014;14(422):1-8.
23. Timilsina S, Bhattarai N, Khanal B, Rijal S. Serological assessment for *Leishmania donovani* infection in blood donors of Sunsari District, Dharan, Nepal. *Indian J Hematol Blood Transfus* 2016;32(1):95-9.
24. Özbel Y, Karakuş M, Arserim SK, Kalkan ŞO, Töz S. Molecular detection and identification of *Leishmania* spp. in naturally infected *Phlebotomus tobbi* and *Sergentomyia dentata* in a focus of human and canine leishmaniasis in western Turkey. *Acta Trop* 2016;155:89-94.
25. Koltas IS, Eroğlu F, Alabaz D, Uzun S. The emergence of *Leishmania major* and *Leishmania donovani* in southern Turkey. *Trans R Soc Trop Med Hyg* 2014;108:154-8.
26. Eroğlu F, Koltas S, Alabaz D, Uzun S, Karakuş M. Clinical manifestations and genetic variation of *Leishmania infantum* and *Leishmania tropica* in Southern Turkey. *Exp Parasitol* 2015;154:67-74.
27. Kurşun E, Turunç T, Demiroğlu YZ, Solmaz S, Arslan H. Evaluation of fourteen adult cases with visceral leishmaniasis. *Mikrobiyol Bul* 2013;47(3):500-6.
28. Salman IS, Vural H, Ünver H, Şaçar S. Cutaneous leishmaniasis cases in Nizip, Turkey after the Syrian Civil War. *Mikrobiyol Bul* 2014;48(1):106-13.
29. Foroutan M, Dalvand S, Khademvatan S, Majidani H, Khalkhali H, Masoumifard S, et al. A systematic review and meta-analysis of the prevalence of leishmania infection in blood donors. *Transfus Apher Sci* 2017;56(4):544-51.
30. Maia-Elkhouy AN, Alves WA, Sousa-Gomes ML, Sena JM, Luna EA. Visceral leishmaniasis in Brazil: trends and challenges. *Cad Saude Publica* 2008;24(12):2941-7.
31. Available from: <https://multeciler.org.tr/turkiyedeki-suriye-li-sayisi/10/04/2019>
32. Gürel MS, Yeşilova Y, Olgen MK, Özbel Y. Türkiye'de kutanöz leishmaniasisin durumu. *Türkiye Parazitoloj Derg* 2012;36:121-9.
33. Perez-Cutillas P, Goyenab E, Chitimiab L, Ruac P, Bernald LJ, Fisa R. Spatial distribution of human asymptomatic *Leishmania infantum* infection in southeast Spain: a study of environmental, demographic and social risk factors. *Acta Trop* 2015;46:127-34.
34. Ayllon T, Diniz PP, Breitschwerdt EB, Villaescusa A, Rodriguez-Franco F, Sainz A. Vector-borne diseases in client-owned and stray cats from Madrid, Spain. *Vector Borne Zoonotic Dis* 2012;12(2):143-50.
35. Can H, Döşkaya M, Özdemir HG, Şahar EA, Karakavuk M, Pektaş B, et al. Seroprevalance of *Leishmania* infection and molecular detection of *Leishmania tropica* and *Leishmania infantum* in stray cats of Izmir, Turkey. *Exp Parasitol* 2016;167:109-14.
36. Paşa S, Tetik Vardarlı A, Erol N, Karakuş M, Töz S, Atasoy A, et al. Detection of *Leishmania major* and *Leishmania tropica* in domestic cats in the Ege Region of Turkey. *Vet Parasitol* 2015;212(3-4):389-92.
37. Paniz Mondolfi AE, Colmenares Garmendia A, Mendoza Perez Y, Hernandez-Pereira CE, Medina C, Vargas F, et al. Autochthonous cutaneous leishmaniasis in urban domestic animals (*Felis catus*/*Canis lupus familiaris*) from central-western Venezuela. *Acta Trop* 2019;191:252-60.
38. Coura FM, Passos SKP, Pelegrino MOF, Leme FOP, Paz GF, Gontijo CMF, et al. Serological, molecular, and microscopic detection of *Leishmania* in cats (*Felis catus*) in Belo Horizonte, Minas Gerais State, Brazil. *Rev Bras Parasitol Vet* 2018;27(4):570-4.

#### Address for Correspondence/Yazışma Adresi

Dr. Öğr. Üyesi Gül BAYRAM

Mersin Üniversitesi Sağlık Hizmetleri

Meslek Yüksekokulu,

Tıbbi Hizmetler ve Teknikler Bölümü,

Tıbbi Laboratuvar Teknikleri,

Mersin-Türkiye

E-mail: gulbayram78@gmail.com